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notherapy because they are overexpressed on the surface of mela-
noma cells. However, immunization with purified gangliosides
results in a very poor immune response, usually mediated by IgM
antibodies. To overcome this limitation, we immunized mice with
R24, a monoclonal antibody (mAb) that recognizes the most
tumor-restricted ganglioside (GD3); our goal was to obtain anti-
idiotype (Id) antibodies bearing the internal image of GD3.
Animals produced anti-Id and anti-anti-Id antibodies. Both anti-Id
and anti-anti-Id antibodies were able to inhibit mAb R24 binding
to GD3. In addition, the anti-anti-Id antibodies were shown to
recognize GD3 directly. Anti-Id and anti-anti-Id mAb were then
selected from two fusion experiments for evaluation. The most
interesting finding emerged from the characterization of the anti-
anti-Id mAb 5.G8. It was shown to recognize two different
GD3-expressing human melanoma cell lines in vitro and to mediate
tumor cell cytotoxicity by complement activation and antibody-
dependent cellular cytotoxicity. The biological activity of the anti-
anti-Id mAb was also tested in a mouse tumor model, in which it
was shown to be a powerful growth inhibitor of melanoma cells.
Thus, activity of the anti-anti-Id mAb 5.G8 matched that of the
prototypic anti-GD3 mAb R24 both in vitro and in vivo. Altogether,
our results indicate that the idiotype approach might produce high
affinity, specific and very efficient antitumor immune responses.
(Cancer Sci 2011; 102: 64–70)
elanomas and other tumors of neuroectodermal origin
have a distinct profile of cell-surface ganglioside
expression.(1) The relevance of these carbohydrate antigens as
immune targets in cancer cells can be inferred from earlier stud-
ies that described the ability of monoclonal antibodies (mAb)
raised against gangliosides to induce complement-dependent
cytotoxicity (CDC) in melanoma, neuroblastoma, sarcoma and
astrocytoma cell lines.(2) Generally, immunization with whole
tumor cells or cell lysates induces low titer IgM antibodies to
carbohydrate antigens, but the use of conjugated vaccines can
produce high titers of IgM and IgG antibodies.(3) The best vac-
cine design involves the conjugation of the antigen to keyhole
limpet hemocyanin (KLH) and the use of saponins QS-21 and
GPI-0100 as adjuvants.(4)
In contrast to normal cells, transformed melanocytes abun-
dantly express disialoganglioside 3 (GD3). R24 is a mouse mAb
that specifically recognizes GD3 and mediates in vitro effector
functions such as CDC and antibody-dependent cellular
cytotoxicity (ADCC).(5) It also stimulates proliferation of GD3-
expressing T cells derived from human peripheral blood(6) and
was shown to enhance lymphocyte RNA expression of IL-4,Cancer Sci | January 2011 | vol. 102 | no. 1 | 64–70IL-10 and IFN-c.(7) Normal melanocytes are not lysed by the
R24-directed immune response due to their low GD3 expres-
sion. In contrast to the potent in vitro activity of R24, its effect
in nu ⁄nu mice bearing human melanoma grafts is much more
modest; tumor inhibition was observed only when R24 treatment
started within 3 days of tumor cell inoculation and no effect was
shown on established tumors.(8) As a single agent, R24 was
shown to induce clinical responses in patients with metastatic
melanoma, including complete remissions.(9,10) Nevertheless,
the dose-dependent toxicity of R24 can be substantial and con-
stitutes a serious limitation for its clinical use.(11–14)
Anti-idiotype (anti-Id) antibodies that mimic a defined anti-
genic epitope are a relatively unexplored albeit potentially use-
ful therapeutic tool. We hypothesized that an anti-Id antibody,
being a protein, should be more immunogenic than GD3, a thy-
mus-independent antigen. In support of this assumption, promis-
ing results have been reported with anti-Id antibodies in the
context of several experimental models based on pathogen-
derived(15–17) and tumor-associated(18–27)antigens. We have
also previously described an anti-Id monoclonal antibody that
was able to mimic glycoprotein carcinoembryonic antigen
(CEA) and elicit an anti-anti-Id mAb that recognized the antigen
in vitro and in vivo.(28–30) In the present study, we immunized
BALB ⁄ c mice with the mAb R24 with the expectation of obtain-
ing anti-Id antibodies bearing the internal image of GD3. Ani-
mals were shown to produce anti-Id and anti-anti-Id antibodies
of IgM and IgG classes. One anti-Id antibody clone was selected
for detailed evaluation. However, the most interesting finding
emerged from the characterization of the anti-anti-Id antibody.
The well-defined prototypic anti-GD3 monoclonal antibody R24
was used as a control in the assays of binding, cytotoxic activity
in vitro and for the ability to protect against tumor challenge.
We found that this anti-anti-Id mAb is a powerful growth inhibi-
tor of melanoma cells in vitro and in vivo.
Materials and Methods
Animals. Eight-week-old female BALB ⁄ c and C57BL ⁄ 6
mice were obtained from the National Institute of Pharmacology
of the Federal University of Sa˜o Paulo (UNIFESP) and from the
Sa˜o Paulo University animal facilities. All animal experiments
were carried out in compliance with the NIH-Guidelines for the
care and use of laboratory animals, and approved by the Animal
Ethics Committee of UNIFESP.doi: 10.1111/j.1349-7006.2010.01771.x
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Fig. 1. Detection of anti-idiotype (Id) and anti-anti-Id antibodies. Five
mice were injected subcutaneously with mAb R24-keyhole limpet
hemocyanin and bled after each immunization to provide pooled sera
for enzyme immunoassays. (A) Inhibition of mAb R24 binding to GD3,
indicating the presence of inhibitory anti-Id antibodies in the serum
samples diluted 1:200. (B) Titration of GD3-binding anti-anti-Id
antibodies in the sera after three immunizations. All assays were
performed in triplicate. Results were analyzed by the t test.
Table 1. Antibody isotyping
mAb Anti-Id Anti-anti-Id Ig isotype
1.F3 X IgM
2.G11 X IgG3
2.C6 X IgG2a
3.B7 X IgG2a
3.A5 X IgG1
4.B2 X IgM
4.C3 X IgG1
4.E8 X IgG2a
5.G8 X IgG1
5.C3 X IgM
5.C12 X IgG2a
5.H9 X IgG2a
5.E3 X IgG2a
All antibodies had kappa light chains. Bold refers to the antibodies
selected for further analysis. Id, idiotype.Cell lines. Culture conditions followed standard protocols.
Additional information is available in the Supporting Informa-
tion.
Immunization. BALB ⁄ c mice were immunized with 100 lg
of purified antibody (R24, 5.E3 or irrelevant mAb), coupled to
KLH (Sigma, St Louis, MO, USA), as previously described.(29)
Production of anti-Id and anti-anti-Id mAb. Two days before
cell fusion, mice received a final booster of 100 lg of KLH-
coupled mAb R24 administered intravenously. Hybridoma
cells were produced as previously described.(31,32) Double
screening, made by both competitive inhibition and indirect
enzyme immunoassays (EIA), allowed the detection of anti-Id
and anti-anti-Id colonies. After cloning by limiting dilution
and expansion of positive clones, large amounts of antibodies
were obtained by the production of ascites in BALB ⁄ c mice.
The mAb were purified by affinity chromatograghy in a Pro-
tein G-Sepharose column (Amersham Biosciences, Uppsala,
Sweden). Immunoglobulin isotyping was performed with a
Mouse Typer Isotyping Panel kit (Bio-Rad Laboratories,
Hercules, CA, USA).
In vivo protection experiment. Immune deficient C57BL ⁄6
mice were generated by a single 6-Gy dose of whole body c-
irradiation from a 137Cs source as previously described;(23–35)
animals were maintained in a semi-sterile environment and fed
with autoclaved meal and water containing 2 mg ⁄mL gentamy-
cin. 1 · 106 SKMel-28 cells in 0.1 mL sterile PBS were inocu-
lated subcutaneously in two sites at the femur base of irradiated
8-week-old C57BL ⁄6 mice on day 1. Four groups of five ani-
mals received an intraperitoneal injection of 50 lg of either one
of the mAb (5.G8, R24 or the irrelevant 5.D11) or 100 lL of
PBS. Injections were administered daily for 7 days from day 1.
The animals were evaluated daily for tumor size by measuring
the two largest diameters as described elsewhere.(36)
Statistical analysis. Statistical analysis was performed using
the GraphPad Prism V.3 statistical software (La Jolla, CA,
USA). Data were analyzed by t-tests when two groups were
compared and by one-way analysis of variance (ANOVA), fol-
lowed by Dunnett’s post-test, in the cases of multiple compari-
sons. A P value <0.05 was considered significant. Means ± SD
are shown.
The EIA, CDC, ADCC and antibody binding assays were per-
formed according to standard protocols. A detailed description
is presented in the Supporting Information.
Results
Evaluation of the antibody response to mAb R24 immunization.
Serum samples from BALB ⁄ c mice immunized with the mAb
R24 conjugated to KLH were analyzed by competitive inhibi-
tion EIA. Figure 1A shows that the pool of sera from mice that
have been immunized twice was able to inhibit 42.20 ± 10.78%
of the binding of the mAb R24 to GD3 adsorbed to a solid
phase. In addition, it was possible to detect the presence of
anti-anti-Id antibodies in the sera by indirect EIA. Figure 1B
shows the titration of GD3-binding anti-anti-Id antibodies in
the sera of mice that have been immunized three times with
the mAb R24.
Isolation of monoclonal antibodies. Given the high titers of
anti-Id and anti-anti-Id antibodies present in the serum of mAb
R24-immunized mice, we decided to use the spleens of these
animals as the source of clonal cell populations for the produc-
tion of both types of antibodies. Two fusion experiments raised
eight anti-Id and five anti-anti-Id mAb. Isotyping of the anti-Id
antibodies revealed one IgM, one IgG1 and six IgG2a isotypes.
Anti-anti-Id antibodies were also checked and two IgM, two
IgG1 and one IgG3 isotypes were identified. All of the obtained
mAb had kappa light chains (Table 1). Two of these antibodies,
5.E3 and 5.G8, were characterized in detail.Ramos et al.Figure 2A shows the inhibition curve of the binding of the
mAb R24 to GD3 using increasing amounts of the anti-Id mAb
5.E3. A 50% binding inhibition was achieved with a 10 lg ⁄mL
concentration. This inhibition curve is similar to that obtained
with other high-affinity anti-Id antibodies described in the litera-
ture.(30,37,38)
Next, we examined the reactivity of the anti-anti-Id mAb
5.G8 against crude extracts of the GD3-positive SKMel-28 cells.
Figure 2B shows the binding activity to the polar lipid fraction
by indirect EIA. The mAb 5.G8 and the positive control
antibody R24 efficiently recognized the fraction containing
glycosphingolipids that includes gangliosides, as opposed to
the irrelevant antibody control (P < 0.001). Altogether, our dataCancer Sci | January 2011 | vol. 102 | no. 1 | 65
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Fig. 2. Characterization of anti-idiotype (Id) and anti-anti-Id mAb.
(A) The anti-Id mAb 5.E3 inhibited the binding of the mAb R24 to
GD3 in a dose-dependent manner over a 0–100 lg ⁄ mL concentration
range. No specific inhibition was observed when an irrelevant mAb
was used as a control. (B) The polar lipid fraction extracted from
SKMel-28 cells was used to coat the enzyme immunoassay plates. The
anti-anti-Id mAb 5.G8 recognized the crude extract similar to the mAb
R24. Statistical analysis was performed by one-way ANOVA with
Dunnett’s post-test. (C) The reactivity of biotinylated mAb 5.E3 was
tested against mAb 5.G8, mAb R24 or an irrelevant mAb. All
experiments were performed in quadruplicate.
Fig. 3. Immunization with the anti-idiotype (Id) mAb 5.E3 induces
GD3-binding anti-anti-Id antibodies. Sera at 1 ⁄ 200 dilution from mice
that were immunized with the mAb 5.E3 or an irrelevant IgG2a mAb,
both coupled to keyhole limpet hemocyanin, were tested by indirect
EIA for the presence of GD3-binding antibodies. Pre-immune sera
were also used as a control. Statistical analysis was performed by the t
test.allowed us to envisage a model in which the mAb R24, 5.E3
and 5.G8 belong to an interactive idiotype-anti-idiotype net-
work. In order to test this model, we biotinylated the anti-Id
mAb 5.E3 and measured its binding ability to the mAb R24 and
to the anti-anti-Id mAb 5.G8. The anti-Id antibody recognized
equally well the mAb R24 and the mAb 5.G8 as illustrated in
Figure 2C.
Anti-GD3 antibodies generated by anti-Id mAb 5.E3 immunization.
Groups of five mice were immunized with the anti-Id mAb 5.E3
or an IgG2a isotype control mAb, both conjugated to KLH.
Figure 3 shows the presence of GD3-binding anti-anti-Id
antibodies in the sera of mice immunized twice with the mAb
5.E3. The reactivity of the sera derived from 5.E3-immunized66animals was significantly higher than that observed with sam-
ples derived from isotype-vaccinated control mice (P < 0.0001).
In addition, no GD3-binding antibody was detected in the
pre-immune sera.
The anti-anti-Id antibody recognizes intact human melanoma
cells. In order to verify whether the anti-anti-Id mAb 5.G8
could recognize the GD3 antigen in its native status in the con-
text of intact cells, we tested its reactivity against intact SKMel-
28 melanoma cells. Figure 4 shows that the mAb 5.G8 and the
control mAb R24 were capable of recognizing 87.73 ± 2.75%
and 100% of the cells, respectively. Similar data were obtained
with another human melanoma cell line, MeWo, that was
65.55 ± 1.42% positive for binding to the mAb 5.G8 and
72.68 ± 1.72% positive for binding to the mAb R24 (Fig. 4). In
contrast, both antibodies have shown a much lower reactivity to
the human keratinocyte cell line Hacat: 16.78 ± 0.47% for the
mAb 5.G8 and 18.96 ± 0.36% for the mAb R24. They have also
reacted very poorly against another epithelial tumor, the human
colon adenocarcinoma CO112 (3.78 ± 0.29% for the mAb 5.G8
and 1.87 ± 0.45% for the mAb R24), and against the murine
embryonic fibroblast cell line NIH3T3 (7.21 ± 3.35% for the
mAb 5.G8 and 9.43 ± 2.40% for the mAb R24).
Cytotoxic activity of the anti-anti Id mAb 5.G8 in vitro. The
mAb 5.G8 was able to promote antibody-mediated complement-
dependent lysis of SKMel-28 cells (Fig. 5A); these cells were
also targets for antibody-dependent cellular cytotoxicity
(Fig. 5B). The specific lysis achieved in the complement fixa-
tion assay was 65.47 ± 13.23% for the mAb 5.G8 and
97.95 ± 0.82% for the mAb R24; the specific lysis values in the
ADCC test were 61.41 ± 1.57% and 71.00 ± 4.49%, respec-
tively. The cytotoxicity levels induced by these antibodies in
both tests were substantially higher than the background levels
produced by the isotype control (P < 0.001). In contrast to the
mAb 5.G8, the mAb R24 could lyse target cells in the absence
of complement or effector cells.
In vivo antitumor activity of the anti-anti-Id mAb 5.G8.
C57BL ⁄6 mice were rendered immune deficient by irradiation
preconditioning and were subsequently inoculated with
GD3-expressing human melanoma SKMel-28 cells. The animals
were divided into four groups that received one of the following
treatments: (i) the mAb 5.G8; (ii) the mAb R24; (iii) an irrele-
vant mAb; or (iv) PBS, as described in the ‘‘Materials and
Methods’’. All mice (5 ⁄5) in the two negative control groups
developed tumors by day 28 compared with 4 ⁄5 and 1 ⁄5 of
the animals injected with the mAb 5.G8 or the mAb R24,doi: 10.1111/j.1349-7006.2010.01771.x
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Fig. 4. Binding of the anti-anti-idiotype (Id) mAb 5.G8 to different
cell lines. The GD3-expressing human melanoma cell lines (SKMel-28
and MeWo) as well as the cell lines Hacat, NIH3T3 and CO112 were
grown in 96-well plates and fixed as described in the Supporting
Information. Primary antibodies were added and a peroxidase-
conjugated goat anti-mouse IgG was used to detect antibody binding.
MAb R24 was used as a positive control and an irrelevant murine IgG1
antibody was used as an isotype control. The assay was performed
eight times.
(B)
(A)
Fig. 5. In vitro biological activities. (A) Complement-mediated
cytotoxicity and (B) antibody-dependent cellular cytotoxicity (ADCC)
assays were performed with purified mAb (50 lg ⁄ mL). The cell line
SKMel-28 was used as the target in both tests. Fresh rabbit serum was
used as the source of complement (diluted 1 ⁄ 8). Complement-
dependent cytotoxicity was calculated by cell viability analysis at the
end of the experiment. For the ADCC assay, peritoneal exudate was
used as the source of effector cells and 51Cr release was quantified
after 48 h incubation. The Effector : Target ratio was 200:1. Both
assays were performed in quadruplicate. Statistical analysis was
performed using one-way ANOVA with Dunnett’s post-test.
Fig. 6. Ability of mAb to inhibit tumor growth in vivo. Four groups
of five C57BL ⁄ 6 mice were irradiated and grafted with SKMel-28 cells
on day 1. During the first 7 days of the experiment, mice received one
of the following treatments: (i) PBS; (ii) irrelevant antibody; (iii) mAb
R24; or (iv) anti-anti-idiotype (Id) mAb 5.G8, as described in the
‘‘Materials and Methods’’. Animals were checked daily for tumor
growth. The average tumor volume recorded during the fourth week
of the experiment was plotted. These results are representative of
three experiments.respectively. Although there was no major difference between the
mAb 5.G8 group and the negative control groups with regards
to the number of tumor-free animals, there were substantialRamos et al.differences in tumor size and growth profile (Fig. 6). Tumor
growth was observed in the two negative control groups as early
as day 17 as opposed to the mice injected with the 5.G8 and
anti-GD3 control antibodies in which the tumors took longer to
be measurable. Figure 6 shows the tumor growth curve between
days 20 and 28 from one representative experiment out of three.
The lesions were barely visible on day 22 in the groups injected
with the mAb 5.G8 or the mAb R24 and the average volume
was smaller than 1 mm3 on day 28 (0.071 ± 0.073 cm3 for 5.G8
and 0.04 ± 0.1 cm3 for R24). Nevertheless, tumor progression
was much more evident in the negative control groups, on day
28 reaching an average volume of 0.480 ± 0.249 cm3 in the
animals that received the irrelevant antibody and 0.513 ±
0.284 cm3 in those that were injected with PBS. The evaluation
on day 28 of tumor growth by ANOVA followed by Dunnett’s
post-test revealed a significant difference between the PBS
control group and the mAb 5.G8 group (P < 0.001) and between
the PBS and the mAb R24 groups (P < 0.001). Similar differ-
ences were found when the irrelevant antibody group was com-
pared with the mAb 5.G8 group (P < 0.05) and with the mAb
R24 group (P < 0.05). In conclusion, the anti-melanoma effect
in vivo demonstrated with the anti-anti-Id mAb 5.G8 was virtu-
ally identical to that observed with the mAb R24 (Fig. 6).
Discussion
Immunological tolerance is a major issue in cancer immunother-
apy. To break the inability of the host’s immune system to recog-
nize and react properly against malignant cells is particularly
challenging given that tumor-associated antigens are self, poorly
immunogenic molecules. Normal melanocytes express the
mono-sialo GM3 as their major ganglioside, whereas the growth
and metastatic potential of malignant melanoma correlate with
excessive synthesis of GD3.(39) Although little is known about
the precise composition of many gangliosides that are expressed
in tumors, shedding of GD3 into the circulation has been
observed in patients bearing certain malignancies.(39) It has been
shown by several groups that this ganglioside might promote
tumor growth and cell–cell adhesion.(40,41) Although GD3 is
present in melanoma cells, its expression in normal tissues is lim-
ited and not related to altered cellular behavior. Altogether, theseCancer Sci | January 2011 | vol. 102 | no. 1 | 67
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reports support the idea that GD3 might be a good target for
the antitumor immune response and suggest the potential useful-
ness of an anti-GD3 antibody-based strategy in cancer ther-
apy.(9,14,42,43) However, as the main antigenic epitopes in GD3
are carbohydrates, only a very weak and T-cell-independent
immune response can be stimulated when it is used as an immu-
nogen. Several attempts have been made to address the therapeu-
tic potential of the anti-GD3-specific immune response.(14,42–50)
Nevertheless, the anti-GD3 immune response was shown to be
short-lived and mainly constituted by IgM antibodies.(1)
The anti-idiotypic antibody approach represents an alternative
to circumvent the poor immunogenicity of GD3 and the toxicity
of the mAb R24(11–14) in cancer therapy. The remarkable ability
of anti-Id antibodies to mimic the original antigen has been
shown in several models.(15–28) Anti-Id antibodies might induce
a specific immune response against tumor-associated antigens,
such as the carcinoembryonic antigen(29,51) and the human high
molecular weight melanoma-associated antigen(52) among oth-
ers.(22–27) In addition, two anti-idiotype R24 antibodies (BEC2
and BEC3) have been previously isolated.(53) Although BEC3
was incapable of eliciting anti-GD3 responses, BEC2 was shown
to induce IgM but no IgG anti-GD3 antibodies in a fraction
(22%) of immunized melanoma patients.(54–56) The application
of these antigen surrogates in cancer immunotherapy is particu-
larly appealing when the antigen is not a protein, as in the case
of gangliosides. However, the fine specificity profile of
anti-GD3 antibodies and of their anti-idiotypic counterparts
might vary considerably with significant differences in bind-
ing, affinity and immunogenicity.(44–50,53) Thus, the search for
novel anti-Id and anti-anti-Id antibodies, such as the ones
described in this paper, might lead to the identification of mole-
cules with the ability to induce high affinity IgG responses with
increased antitumor activity in a larger fraction of immunized
individuals.
In the present report, we have used the mAb R24 coupled to
KLH to immunize BALB ⁄ c mice. An anti-Id immune response
was identified after the first immunization as the serum inhibited
binding of the mAb R24 to GD3. Anti-anti-Id antibodies capable
of binding GD3 could also be detected in the third immuniza-
tion. In view of these results, both anti-Id and anti-anti-Id mAb
were produced in mice in order to evaluate the efficiency of the
GD3-associated idiotypic network. We found that the anti-Id
and anti-anti-Id antibody secreting clones belonged to different
Ig classes and subclasses. The observed Ig isotype diversity sug-
gests an effective T cell cooperation in the development of the
anti-Id and anti-anti-Id immune responses; it is also likely to
contribute to a higher efficiency of the immune response
because it might augment the cytotoxic effect triggered and ⁄or
mediated by antibodies.
The monoclonal anti-Id antibody selected for detailed analysis
in the present study, clone 5.E3, was able to inhibit the binding
of the mAb R24 to GD3 in a dose-dependent fashion. When
used as an immunogen, the mAb 5.E3 also elicited a GD3-bind-
ing anti-anti-Id humoral immune response in mice. The partici-
pation of the mAb 5.E3 in a cascade of idiotype–anti-idiotype
interactions is supported by its ability to bind the mAb R24 as
well as the anti-anti-Id mAb 5.G8.
The mAb 5.G8 and the mAb R24 were capable of recognizing
the GD3 ganglioside in the polar lipid fraction of SKMel-28 cell
extracts. Reactivity of the anti-anti-Id antibody was also tested
in intact cells; five cell lines, including two human GD3-
expressing melanoma cell lines, were tested for antibody bind-
ing. The mAb 5.G8 was shown to recognize both melanoma cell
lines at comparable levels to those obtained with the original
anti-GD3 mAb R24. It is noteworthy that both antibodies recog-
nized SKMel-28 cells somewhat better than MeWo cells (25%
higher reactivity); this finding is in agreement with the reported
higher expression of GD3 in SKMel-28 cells.(8)68Antibody-dependent cellular cytotoxicity and CDC are
important immune effector mechanisms and the ability to pro-
mote target lysis might be a valuable asset of antibodies con-
sidered for therapeutic use. Our analysis of the mAb 5.G8
revealed that it was highly effective in mediating lysis of
target cells either by ADCC or by fixing complement. The
ADCC activity was observed when activated peritoneal macro-
phages were used as effector cells, but not when splenocytes
were the source of the effector cells (data not shown). At first
sight, the mAb 5.G8 seemed to be less efficient than the mAb
R24 in ADCC and CDC. However, the mAb R24 exhibits
direct cytotoxic activity as evidenced by the aggregation of
melanoma cells in culture, which usually leads to detachment
and subsequent death.(8) In addition, the mAb R24 is an
IgG3 that might form noncovalent molecular aggregates at a
high concentration, thereby increasing the lysis of target cells
in vitro.(57–60) If one accounts for this direct cytotoxicity, the
mAb R24 and the mAb 5.G8 have fairly similar activities in
ADCC and CDC. Indeed, our results indicate that the mAb
5.G8 was even slightly more efficient than the mAb R24 in its
ability to fix complement (59.83 ± 12.29% for the mAb 5.G8
and 52.66 ± 0.82% for the mAb R24), as well as to promote
ADCC (58.34 ± 1.57% and 49.20 ± 2.78%, respectively) if
one discounts in each case the lysis obtained by the antibody
alone.
In our in vivo tumor model, animals were preconditioned by
sublethal irradiation and inoculated with the human melanoma
cell line SKMel-28. All animals in the negative control groups
developed tumors that were approximately 0.5 cm3 on day 28.
This was in sharp contrast with groups that were treated with the
anti-anti-Id or GD3-specific antibodies in which there were
tumor-free animals at the end of the observation period and the
average volume of the lesions when present was under 1 mm3.
Thus, our data indicate that passive transfer of the anti-anti-Id
mAb 5.G8 confers protection in the experimental model
described here by delaying tumor growth.
We present evidence that immunization with the anti-GD3
mAb R24 induces a cascade of idiotype–anti-idiotype interac-
tions. While anti-Id interactions are likely to occur in the context
of natural immune responses, a definitive picture of their
immune-regulatory importance remains to be established. How-
ever, our results demonstrate that the anti-Id approach works
even in a T-cell-independent system and suggests a potential
role to play in cancer immunotherapy. The isotype diversity also
constitutes an advantage of the anti-Id strategy; this is particu-
larly relevant if we consider that such diversity occurred in a
system where the original antigen is a glycolipid that is unlikely
to stimulate an efficient immune response on its own. To our
knowledge, this is the first report on a melanoma-specific anti-
anti-Id mAb that shows direct antitumor activity in vivo in a
T-cell-independent way; this anti-anti-Id mAb might represent
an alternative for cancer treatment if further studies identify a
favorable profile in terms of toxicity, inflammatory reaction and
tumor killing.
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